Clinical trial · Interventional
CIRculating Cell-free nUcLeic Acids in Cancer Therapy Monitoring -01
NCT05871593CI-TRIAL-00066612CIRCULATING-01not yet recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In cooperation with the molecular tumor board of the University Hospital Tübingen (UKT), a prospective collection of blood samples during the course of therapy is planned. It is a pilot study in which the technical feasibility of the approach (Highly Sensitive Next-Generation Sequencing (NGS) methods) initially should to be evaluated and further developed.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Next-Generation-Sequencing | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Molecular genetic diagnostic | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Molecular genetic diagnostic
- description
- Next-Generation-Sequencing (NGS)-methods
- interventionNames
- Genetic: Molecular genetic diagnostic
Primary outcomes (3)
- measure
- cfDNA/cfRNA
- timeFrame
- Day 1: Preoperative
- description
- Ratio of cfDNA/cfRNA preoperative
- measure
- cfDNA/cfRNA
- timeFrame
- Day 2: At intervals of approx. 6-10 weeks
- description
- Ratio of cfDNA/cfRNA during therapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years * Advanced tumor disease * Ability to consent * Existence of a declaration of consent signed by the patient and physician (informed consent for study participation and Comprehensive Cancer Center (CCC) biobank * Existence or planned implementation of tumor-normal sequencing (usually carried out in a diagnostic context upon presentation at the Molecular Tumor Board (MTB) Exclusion Criteria: \- No therapy recommendation by MTB
References
Publications (0)
Data not yet available
No reference posted for this study.